Doximity shares soar 25% after company beats on revenue, raises fiscal-year guidance
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Bristol Myers' stock decline in response to weak guidance is a gift to investors
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
Teladoc Health to acquire Catapult Health in $65 million deal
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Healthy Returns: Why people quit weight loss and diabetes drugs within one year
